Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12619000946112
Ethics application status
Approved
Date submitted
20/06/2019
Date registered
5/07/2019
Date last updated
29/06/2021
Date data sharing statement initially provided
5/07/2019
Date results provided
29/06/2021
Type of registration
Prospectively registered
Titles & IDs
Public title
Boostability of One priming dose intramuscular Rabies vaccine especially in Senior age groups
Query!
Scientific title
Boostability of One priming dose intramuscular Rabies vaccine especially in Senior age groups
Query!
Secondary ID [1]
298521
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
BORS
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Rabies
313371
0
Query!
Condition category
Condition code
Infection
311813
311813
0
0
Query!
Other infectious diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Intramuscular (deltoid) administration of 0.5ml of Verorab (containing not less than 2.5 international units of inactivated Wistar rabies virus strain per 0.5ml) at days 0, 60, and 63
Query!
Intervention code [1]
314803
0
Prevention
Query!
Comparator / control treatment
No control
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
320484
0
Antibodies titer levels to rabies virus (IU/mL) using serum assay (Platella Rabies II ELISA)
Query!
Assessment method [1]
320484
0
Query!
Timepoint [1]
320484
0
60 days post initial vaccination
Query!
Primary outcome [2]
320561
0
Antibodies titer levels to rabies virus (IU/mL) using serum assay (Platella Rabies II ELISA)
Query!
Assessment method [2]
320561
0
Query!
Timepoint [2]
320561
0
67 days post initial vaccination
Query!
Secondary outcome [1]
371776
0
Self-reported side effects of the vaccination (e.g. injection site reactions [pain, swelling, itching, or redness], headache, dizziness, muscle pain, nausea, pain)
Query!
Assessment method [1]
371776
0
Query!
Timepoint [1]
371776
0
74 days post initial vaccination
Query!
Secondary outcome [2]
372024
0
Antibodies titer levels to rabies virus (IU/mL) using serum assay (Platella Rabies II ELISA)
Query!
Assessment method [2]
372024
0
Query!
Timepoint [2]
372024
0
81 days post initial vaccination
Query!
Eligibility
Key inclusion criteria
1. No prior history of rabies vaccination
2. Able to give written Informed Consent and sign consent after all aspects of the protocol have been explained
3. Subject must agree to participate in three doses of vaccine, three to four blood tests and two questionnaires including the planned follow-up telephone review
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
1. Taking medications that impair the normal functioning of the immune system
2. Pregnancy or planning pregnancy
3. Travelling to areas of high risk for rabies where an unusual pre-exposure prophylaxis schedule may cause difficulty in the event of an animal exposure that requires post-exposure prophylaxis
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
1/09/2019
Query!
Actual
17/01/2020
Query!
Date of last participant enrolment
Anticipated
1/09/2020
Query!
Actual
2/10/2020
Query!
Date of last data collection
Anticipated
1/12/2020
Query!
Actual
4/12/2020
Query!
Sample size
Target
100
Query!
Accrual to date
Query!
Final
103
Query!
Recruitment in Australia
Recruitment state(s)
QLD
Query!
Funding & Sponsors
Funding source category [1]
303065
0
Other
Query!
Name [1]
303065
0
Dr Deb The Travel Doctor Pt Ltd
Query!
Address [1]
303065
0
5/247 Adelaide St, Brisbane City QLD 4000
Query!
Country [1]
303065
0
Australia
Query!
Primary sponsor type
Individual
Query!
Name
Luis Furuya-Kanamori
Query!
Address
Australian National University Research School of Population Health 62 Mills Road Acton, ACT 2601
Query!
Country
Australia
Query!
Secondary sponsor category [1]
303085
0
None
Query!
Name [1]
303085
0
Query!
Address [1]
303085
0
Query!
Country [1]
303085
0
Query!
Other collaborator category [1]
280749
0
Individual
Query!
Name [1]
280749
0
Colleen Lau
Query!
Address [1]
280749
0
Australian National University
Research School of Population Health
62 Mills Road
Acton, ACT 2601
Query!
Country [1]
280749
0
Australia
Query!
Other collaborator category [2]
280750
0
Individual
Query!
Name [2]
280750
0
Deborah Mills
Query!
Address [2]
280750
0
Dr Deb The Travel Doctor Pt Ltd
5/247 Adelaide St, Brisbane City QLD 4000
Query!
Country [2]
280750
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
303615
0
Australian National University Human Research Ethics Committee
Query!
Ethics committee address [1]
303615
0
Level 1, Geography Building, Building 48A Linnaeus Way,The Australian National University Acton, ACT 2601
Query!
Ethics committee country [1]
303615
0
Australia
Query!
Date submitted for ethics approval [1]
303615
0
14/06/2019
Query!
Approval date [1]
303615
0
09/09/2019
Query!
Ethics approval number [1]
303615
0
2019/451
Query!
Summary
Brief summary
Rabies is a fatal disease, present in most countries outside Australia, so poses a risk to Australian travellers. Although deaths in travellers are rare (60 reported cases 1990 – 2012 ), rabies risk exposures are relatively common (2-13/1000 travellers per month). In travellers who are aware the horrors of this untreatable disease, a potential rabies exposure can be stressful, and cause major disruption to travel plans in the quest for appropriate treatment. Pre-exposure rabies vaccination (PrEP) simplifies the treatment of animal exposures if they occur during travel. The standard recommendations for rabies PrEP is to give 2-3 doses of vaccine prior to departure. The Australian guidelines recommend PrEP - one dose of Rabies vaccine given on day 0,7,and 21-28. Many travellers are leaving at short notice and do not have time to complete this pre departure rabies vaccine course. Recent research has suggested that two doses or even one dose may be sufficient to prime the immune system, and simplify the post exposure treatment of at risk animal exposures. Much of the research in the past has be done on young soldiers. There is very limited research in persons over the age of 50 years to confirm that persons in this age group mount an adequate immune response to lower doses of rabies vaccine.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
94270
0
Dr Luis Furuya-Kanamori
Query!
Address
94270
0
Australian National University
Research School of Population Health
62 Mills Road
Acton, ACT 2601
Query!
Country
94270
0
Australia
Query!
Phone
94270
0
+61 (02) 6125 2145
Query!
Fax
94270
0
Query!
Email
94270
0
[email protected]
Query!
Contact person for public queries
Name
94271
0
Luis Furuya-Kanamori
Query!
Address
94271
0
Australian National University
Research School of Population Health
62 Mills Road
Acton, ACT 2601
Query!
Country
94271
0
Australia
Query!
Phone
94271
0
+61 (02) 6125 2145
Query!
Fax
94271
0
Query!
Email
94271
0
[email protected]
Query!
Contact person for scientific queries
Name
94272
0
Luis Furuya-Kanamori
Query!
Address
94272
0
Australian National University
Research School of Population Health
62 Mills Road
Acton, ACT 2601
Query!
Country
94272
0
Australia
Query!
Phone
94272
0
+61 (02) 6125 2145
Query!
Fax
94272
0
Query!
Email
94272
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
The dataset may contain personal and medical information from the participants' that could potentially be used for re-identification. Only aggregated or summary results will be shared.
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Doc. No.
Type
Citation
Link
Email
Other Details
Attachment
2748
Ethical approval
Once the ethics approval letter is received, it wi...
[
More Details
]
377803-(Uploaded-10-09-2019-07-39-03)-Study-related document.pdf
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
Source
Title
Year of Publication
DOI
Embase
Efficacy of one-dose intramuscular rabies vaccine as pre-exposure prophylaxis in travellers.
2021
https://dx.doi.org/10.1093/jtm/taab059
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF